How to Read a AOD-9604 Certificate of Analysis (COA)
A Certificate of Analysis is only useful if you know which number on it matters for the compound in front of you. For AOD-9604, the informative checks are not the same as for a generic short peptide.
Overview
We have not published a certificate for this batch yet, so no purity figure is claimed for it. When one is posted, look at HPLC purity and the amount actually in the vial. If a mass is given, it should be about 1815; a peak about 2 heavier means the bridge has opened.
What AOD-9604 actually is
AOD-9604 is a 16-part lab-made peptide copied from the very end of human growth hormone, with one extra building block (tyrosine) added at the front and a single sulfur-sulfur bridge holding it in a loop. Animal studies from the early 2000s looked at how it affects fat metabolism, and a later rabbit study looked at joint cartilage. It was developed in Australia as an obesity drug candidate, but that programme was stopped in 2007 and it was never approved as a medicine.
Supplied for laboratory research use only — not for human or animal use.
Third-party tested by HPLC and LC-MS, ≥99% purity, with a Certificate of Analysis on every order. Ships across Canada.
Technical detail below
Assays that are informative for AOD-9604
What to check on the COA
Where mass data is given, the oxidised (disulfide-closed) target is about 1815.1 Da average, 1813.86 Da monoisotopic. A peak near 1817 Da indicates the reduced, open-chain form; a species near twice the mass indicates a disulfide-linked dimer. Check peptide content separately from HPLC purity.
Reduced (open-chain) monomer, disulfide-linked dimers, and deletion sequences from synthesis.
Verify a Popular Peptides batch
Every batch is third-party tested by HPLC and LC-MS with a published Certificate of Analysis (≥99% purity). Enter a lot number to pull the COA for the exact vial in front of you.
What AOD-9604 is studied for
Heffernan et al. (Endocrinology 2001) compared hGH and AOD9604 over 14 days in obese mice and in β3-adrenergic-receptor knockout mice. Both raised the repressed β3-AR expression in obese mice, but neither changed body weight or lipolysis in the knockout mice over the long-term protocol, leading the authors to conclude the lipolytic actions were not mediated directly through β3-AR.
Ng et al. (Horm Res 2000) studied oral administration of AOD9604 in obese Zucker rats, reporting reduced body-weight gain and increased adipose lipolytic activity, and — unlike intact hGH — no impairment of insulin sensitivity on euglycaemic clamp.
Stier et al. (J Endocrinol Metab 2013) pooled six randomised, double-blind, placebo-controlled trials and reported no change in serum IGF-1, no adverse effect on carbohydrate metabolism, and no anti-AOD9604 antibodies in tested participants. The same development programme did not show a clinically meaningful weight outcome.
Kwon and Park (Ann Clin Lab Sci 2015) gave intra-articular AOD9604, with or without hyaluronic acid, in a collagenase-induced knee osteoarthritis model in rabbits and scored cartilage morphology, histology and lameness.
Summarizes published preclinical literature — see the selected references below. Provided for research reference only; not a claim of efficacy or a description of human use.
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001.
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000.
- Stier H, Vos E, Kenley D Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013.
- Kwon DR, Park GY Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of Clinical & Laboratory Science. 2015.
- Browse current AOD-9604 literature on PubMed
References describe in-vitro and preclinical research and are listed for reference only — not evidence of efficacy and not a description of human use.
More AOD-9604 reference
Lyophilized and reconstituted storage conditions, plus the practical working window.
Diluent selection, dissolution behaviour, and the calculator preset for this compound.
Which solvents work, why, and what abnormal dissolution behaviour indicates.
The specific chemical routes by which this molecule breaks down, and how to limit each.
Compound-specific bench practices, and the errors most often made with this molecule.
What to inspect on arrival, and which conditions actually warrant rejecting a vial.
Questions specific to this compound — structure, chemistry, and common misconceptions.
Purity & COA reference for other compounds
Reviewed for research-use compliance by Kobi Williams, Founder — Popular Peptides Canada. Last reviewed 22 July 2026.
AOD-9604 is supplied strictly as a research chemical for in-vitro laboratory and research use only. It is not intended for human or animal consumption, diagnostic, or therapeutic use. This page is educational laboratory-handling reference information — not medical advice, not usage guidance, and not a protocol.